Trial
NCT01636817
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Inflammation
Intervention
NNC0109-0012
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-05